Teva Pharmaceutical (NYSE: TEVA) reported Q2 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.08 billion.

EPS guidance for 2014 improved to $4.90-5.10 in the exclusive Copaxone scenario, and to $4.50-4.80 in the generic Copaxone® scenario. The consensus is at $4.82.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.